碱基编辑CAR T细胞用于T细胞恶性肿瘤的联合治疗
研究通过碱基编辑有序敲除TCR/CD3与CD7,再经慢病毒表达抗CD3或CD7的CAR,生成抗自相残杀的T细胞。3CAR/7CAR共培养可自富集出99.6% TCR-/CD3-/CD7-群体,在体外及人鼠嵌合模型中對CD3+CD7+T-ALL展现最高细胞毒性,且未发现影响CAR抗原特异性结合的脱靶编辑。
要点
- 碱基编辑可无缝敲除TCR/CD3与CD7,避免CAR T对T细胞恶性肿瘤的自相残杀。
- 3CAR/7CAR共培养自富集出99.6% TCR-/CD3-/CD7-细胞群。
- 联合输注抗T CAR T或可在allo-HSCT前增强T细胞恶性肿瘤的分子缓解。
核心结论
- 碱基编辑生成的抗自相残杀抗T CAR T细胞可联合用于T细胞恶性肿瘤治疗。
研究设计与样本
- 研究通过碱基编辑有序敲除TCR/CD3与CD7后,用慢病毒表达抗CD3或CD7的CAR。
主要发现
- 3CAR/7CAR共培养自富集出99.6% TCR-/CD3-/CD7-细胞群。
- 3CAR或7CAR细胞对表达CD3和/或CD7的白血病细胞系及原代T-ALL细胞有特异性细胞毒性。
- 共培养的3CAR/7CAR细胞在体外及人鼠嵌合模型中对CD3+CD7+T-ALL靶细胞展现最高细胞毒性。
- 未发现影响CAR抗原特异性结合的脱靶活性或混杂碱基转换。
临床怎么用
- 联合输注抗自相残杀抗T CAR T细胞可能作为allo-HSCT前增强分子缓解的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeting T cell malignancies using chimeric antigen receptor (CAR) T cells is hindered by 'T v T' fratricide against shared antigens such as CD3 and CD7. Base editing offers the possibility of seamless disruption of gene expression of problematic antigens through creation of stop codons or elimination of splice sites. We describe the generation of fratricide-resistant T cells by orderly removal of TCR/CD3 and CD7 ahead of lentiviral-mediated expression of CARs specific for CD3 or CD7. Molecular interrogation of base-edited cells confirmed elimination of chromosomal translocations detected in conventional Cas9 treated cells. Interestingly, 3CAR/7CAR co-culture resulted in 'self-enrichment' yielding populations 99.6% TCR-/CD3-/CD7-. 3CAR or 7CAR cells were able to exert specific cytotoxicity against leukaemia lines with defined CD3 and/or CD7 expression as well as primary T-ALL cells. Co-cultured 3CAR/7CAR cells exhibited highest cytotoxicity against CD3 + CD7 + T-ALL targets in vitro and an in vivo human:murine chimeric model. While APOBEC editors can reportedly exhibit guide-independent deamination of both DNA and RNA, we found no problematic 'off-target' activity or promiscuous base conversion affecting CAR antigen-specific binding regions, which may otherwise redirect T cell specificity. Combinational infusion of fratricide-resistant anti-T CAR T cells may enable enhanced molecular remission ahead of allo-HSCT for T cell malignancies.
引用
- Georgiadis C, Rasaiyaah J, Gkazi SA, et al. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia. 2021. PMID: 34035409. doi:10.1038/s41375-021-01282-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。